PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25524470-0	2015	Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of autophagy in human colon cancer cells.	Deferoxamine	0-12	TNF superfamily member 10	Homo sapiens	22-27	
25524470-3	2015	The present study investigated the effects of DFO on TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in colon cancer cells and and the mechanism involved.	Deferoxamine	46-49	TNF superfamily member 10	Homo sapiens	53-90	
25524470-3	2015	The present study investigated the effects of DFO on TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in colon cancer cells and and the mechanism involved.	Deferoxamine	46-49	TNF superfamily member 10	Homo sapiens	92-97	
25524470-4	2015	The experimental results showed that DFO treatment inhibited TRAIL-mediated cancer cell apoptosis by increasing Akt activation and decreasing caspase activation in human colon cancer cells.	Deferoxamine	37-40	TNF superfamily member 10	Homo sapiens	61-66	
25524470-5	2015	Furthermore, DFO treatment induced autophagy flux, and chloroquine, an autophagy inhibitor, blocked DFO-mediated inhibition of TRAIL-induced apoptosis.	Deferoxamine	100-103	TNF superfamily member 10	Homo sapiens	127-132	
25524470-6	2015	The present study demonstrated that DFO inhibited TRAIL-mediated tumor cell death via the autophagy pathway, and the results suggest that potent anticancer agent, DFO, can be an inhibitor against antitumor therapy including TRAIL protein.	Deferoxamine	36-39	TNF superfamily member 10	Homo sapiens	50-55	
25524470-6	2015	The present study demonstrated that DFO inhibited TRAIL-mediated tumor cell death via the autophagy pathway, and the results suggest that potent anticancer agent, DFO, can be an inhibitor against antitumor therapy including TRAIL protein.	Deferoxamine	36-39	TNF superfamily member 10	Homo sapiens	224-229	
25524470-6	2015	The present study demonstrated that DFO inhibited TRAIL-mediated tumor cell death via the autophagy pathway, and the results suggest that potent anticancer agent, DFO, can be an inhibitor against antitumor therapy including TRAIL protein.	Deferoxamine	163-166	TNF superfamily member 10	Homo sapiens	50-55	
25524470-6	2015	The present study demonstrated that DFO inhibited TRAIL-mediated tumor cell death via the autophagy pathway, and the results suggest that potent anticancer agent, DFO, can be an inhibitor against antitumor therapy including TRAIL protein.	Deferoxamine	163-166	TNF superfamily member 10	Homo sapiens	224-229